OTCBB:LIXT

Lixte Biotechnology Holdings Stock News

Healthcare > Biotechnology

Buy LIXT

*Your capital is at risk

$7.30

-0.180 (-2.41%)

At Close: Jun 23, 2026

Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

09:00am, Thursday, 18'th Dec 2025

BOCA RATON, FLA, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the "Company"), a biotech company focused on advancing cancer treatments, today announced that it

LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities

08:30am, Monday, 08'th Dec 2025

BOCA RATON, FL / ACCESS Newswire / December 8, 2025 / In recent years, LIXTE (NASDAQ:LIXT) has been defined by LB-100, its first-in-class PP2A inhibitor with a mechanism that unlocks new therapeutic a

LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology

11:00am, Wednesday, 03'rd Dec 2025

BOCA RATON, FL / ACCESS Newswire / December 3, 2025 / For a micro-cap biotech, the usual headlines bounce between cash raises, compliance updates, and board-room reshuffles. Once in a while, though, o

LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers

08:00am, Wednesday, 03'rd Dec 2025

BOCA RATON, FL / ACCESS Newswire / December 3, 2025 / Oncology has spent decades chasing the next magic bullet. The twist is that the next breakthrough may not be a bullet at all.

LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment

08:30am, Tuesday, 25'th Nov 2025

Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology BOCA RATON, Fla., Nov. 25, 202

LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3

08:00am, Wednesday, 29'th Oct 2025

BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT, LIXTW), a clinical-stage pharmaceutical company advancing LB-10

LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans

08:00am, Thursday, 16'th Oct 2025

Company underscores clinical execution and confirms advanced negotiations underway on acquisition of complementary oncology assets BOCA RATON, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechno

LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT)

08:30am, Tuesday, 16'th Sep 2025

BOCA RATON, FL / ACCESS Newswire / September 16, 2025 / For a small-cap biotech, the headlines often center on fundraising, partnerships, or meeting exchange requirements. But every so often, the spot

LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)

05:40pm, Monday, 15'th Sep 2025

BOCA RATON, FL / ACCESS Newswire / September 15, 2025 / For most small-cap biotechs, the summer months mean quiet trial work and the occasional conference slide deck. LIXTE Biotechnology Holdings (NAS

LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions

04:05pm, Wednesday, 10'th Sep 2025

BOCA RATON, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today anno

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by